ANLN: A Potential Drug Target and Biomarker (G54443)
ANLN: A Potential Drug Target and Biomarker
ANLN (alpha-latestin) is a protein that is expressed in various tissues of the human body, including the brain, heart, and kidneys. It is a member of the neurotrophic factor family, which includes proteins that are involved in the process of neurotransmission and neuroregeneration. ANLN has been shown to play a role in the development and progression of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and neurodegenerative diseases. As a result, ANLN has become a focus of interest for researchers studying these conditions, as well as for the development of potential therapeutic approaches.
The Alpha-Latestin gene
The ANLN gene is located on chromosome 11q22 and encodes a protein that is 190 amino acids long. The protein is composed of four distinct domains: an N-terminus, a transmembrane region, a cytoplasmic tail, and a C-terminus. The N-terminus of ANLN contains a 24 amino acid alpha-helic acid that is involved in the formation of the protein's alpha-helicase domain. The transmembrane region consists of four amino acids that are involved in the formation of the protein's beta-sheet structure. The cytoplasmic tail consists of four amino acids that are involved in the protein's stability and localization to the endoplasmic reticulum. The C-terminus of ANLN contains a 24 amino acid C-terminal domain that is involved in the protein's interaction with other proteins.
Function
ANLN is involved in a variety of physiological processes in the body, including neurotransmission and neuroregeneration. It is a potent regulator of neurotrophic factor (NTF) signaling, which is a critical pathway involved in the regulation of neurotransmitter release and neurotransmission. ANLN has been shown to play a role in the regulation of NTF signaling by interacting with the protein TrkB.
ANLN is also involved in the regulation of cell survival and proliferation. It has been shown to play a role in the regulation of cell survival and proliferation by interacting with the protein Bcl-2.
Anln's role in neurological disorders
ANLN has been implicated in the development and progression of a variety of neurological disorders, including Alzheimer's disease, Parkinson's disease, and neurodegenerative diseases.
In the context of Alzheimer's disease, ANLN has been shown to be involved in the regulation of neurotransmission and neurodegeneration in the brain. Studies have shown that ANLN levels are decreased in the brains of individuals with Alzheimer's disease, and that these levels are associated with the severity of the disease. Additionally, ANLN has been shown to play a role in the regulation of the neurotransmitter acetylcholine, which is involved in the development of neurodegeneration in the brain.
In the context of Parkinson's disease, ANLN has been shown to be involved in the regulation of neurotransmission and neurodegeneration in the brain. Studies have shown that ANLN levels are decreased in the brains of individuals with Parkinson's disease, and that these levels are associated with the severity of the disease. Additionally, ANLN has been shown to play a role in the regulation of the neurotransmitter dopamine, which is involved in the development of neurodegeneration in the brain.
In the context of neurodegenerative diseases, ANLN has been shown to be involved in the regulation of neurotransmission and neurodegeneration in various tissues. Studies have shown that ANLN levels are decreased in the brains of individuals with neurodegenerative diseases, and that these levels are associated with the severity of the disease. Additionally, ANLN has been shown to play a role in
Protein Name: Anillin, Actin Binding Protein
Functions: Required for cytokinesis (PubMed:16040610). Essential for the structural integrity of the cleavage furrow and for completion of cleavage furrow ingression. Plays a role in bleb assembly during metaphase and anaphase of mitosis (PubMed:23870127). May play a significant role in podocyte cell migration (PubMed:24676636)
The "ANLN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANLN comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
Annexin | ANO1 | ANO10 | ANO2 | ANO3 | ANO4 | ANO5 | ANO6 | ANO7 | ANO7L1 | ANO8 | ANO9 | Anoctamin | ANOS1 | ANOS2P | ANP32A | ANP32A-IT1 | ANP32AP1 | ANP32B | ANP32C | ANP32D | ANP32E | ANPEP | ANTKMT | ANTXR1 | ANTXR2 | ANTXRL | ANTXRLP1 | ANXA1 | ANXA10 | ANXA11 | ANXA13 | ANXA2 | ANXA2P1 | ANXA2P2 | ANXA2P3 | ANXA2R | ANXA2R-AS1 | ANXA2R-OT1 | ANXA3 | ANXA4 | ANXA5 | ANXA6 | ANXA7 | ANXA8 | ANXA8L1 | ANXA8L2 | ANXA9 | AOAH | AOC1 | AOC2 | AOC3 | AOC4P | AOPEP | AOX1 | AOX2P | AP-1 Transcription Factor Complex | AP1AR | AP1B1 | AP1B1P1 | AP1G1 | AP1G2 | AP1M1 | AP1M2 | AP1S1 | AP1S2 | AP1S3 | AP2A1 | AP2A2 | AP2B1 | AP2M1 | AP2S1 | AP3B1 | AP3B2 | AP3D1 | AP3M1 | AP3M2 | AP3S1 | AP3S2 | AP4B1 | AP4B1-AS1 | AP4E1 | AP4M1 | AP4S1 | AP5B1 | AP5M1 | AP5S1 | AP5Z1 | APAF1 | APBA1 | APBA2 | APBA3 | APBB1 | APBB1IP | APBB2 | APBB3 | APC | APC2 | APCDD1 | APCDD1L
